Philadelphia, PA (January 18, 2012) – eviti, Inc. (formerly known as ITA Partners, Inc.) announced today that it has deployed eviti® | Clinical Trials as an enhancement to its oncology decision-support platform. Physicians using the eviti solution now have access to information on thousands of federally registered cancer clinical trials at the moment of clinical prescribing. Clinicians can view available trials by city and state, facility, and practice. And when used as part of eviti® | Connect for treatment pre-authorization, payers will know if a patient qualifies for the proposed clinical trial and what components of the clinical trial represent routine care versus experimental care.
The integration of clinical trials into eviti benefits all parties involved:
- Patients receive assurance that their physician can easily identify and suggest appropriate clinical trials as part of their full range of treatment options;
- Physicians have access to the latest nationally-recognized evidence-based treatment options and appropriate clinical trials to determine the most beneficial treatment for the patient;
- Payers are assured that all the options presented through eviti, including clinical trials, fit the patient’s diagnosis, and that they are reimbursing for appropriate care.
“It is our belief as a company that physicians, patients and payers should consider clinical trials as a viable treatment option up front. By integrating clinical trials into eviti, we’re bringing high-quality clinical trial options to physicians at the point of prescribing,” said Eduardo Beruff, President and CEO, eviti, Inc.
With the addition of eviti® | Clinical Trials, the eviti platform will offer both a comprehensive knowledge base of over 1,100 evidence-based treatments and thousands of clinical trials, covering all treatment modalities for more than 120 cancer types.
About eviti, Inc.
eviti, Inc. is a leading health information technology company delivering web-based decision-support services to improve the quality of cancer care and reduce its cost. eviti represents the culmination of almost a decade of experience providing oncology treatment intelligence, uniquely delivering value to all parties in the care process by ensuring quality care is prescribed from the start.
eviti’s growing national prominence is evidenced by the 4,500 oncologists already registered to use the eviti platform. eviti’s independent, non-proprietary digital oncology treatment library is one of the most comprehensive and current of its kind, meticulously compiled from the world’s leading sources. eviti’s treatment knowledge base and patent-pending decision-support engine help oncologists select a treatment option that is both evidence-based and compliant with each patient’s insurance plan language at the moment of prescribing. This transparent approach streamlines workflow and reimbursement, reduces variability in clinical care, and results in cost efficiencies. eviti allows the best cancer care to be available everywhere. For more information, visit www.eviti.com.